UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B/NS3 and blocks replication organelle formation

Nature communications, 2024-07, Vol.15 (1), p.6080-20, Article 6080

2024

Volltextzugriff (PDF)

Multiplexed multicolor antiviral assay amenable for high-throughput research

Nature communications, 2024-01, Vol.15 (1), p.42-15, Article 42

2024

Volltextzugriff (PDF)

Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics

PLoS computational biology, 2023-12, Vol.19 (12), p.e1011662-e1011662

2023

Volltextzugriff (PDF)

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

Journal of Virology, 2008-11, Vol.82 (21), p.10366-10374

2008

Volltextzugriff (PDF)

A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction

Nature (London), 2021-10, Vol.598 (7881), p.504-509

2021

Volltextzugriff (PDF)

Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery

Antiviral research, 2019-08, Vol.168, p.109-113

2019

Volltextzugriff (PDF)

Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics

PLoS computational biology, 2023-12, Vol.19 (12)

2023

Volltextzugriff (PDF)

Therapeutics for flaviviral infections

Antiviral research, 2023-02, Vol.210, p.105517-105517, Article 105517

2023

Volltextzugriff (PDF)

A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships

Antiviral research, 2023-02, Vol.210, p.105495, Article 105495

2023

Volltextzugriff (PDF)

Discovery of JNJ-1802, a First-in-Class Pan-Serotype Dengue Virus NS4B Inhibitor

Journal of medicinal chemistry, 2024-03, Vol.67 (5), p.4063-4082

2024

Volltextzugriff (PDF)

Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates

Nature (London), 2023-03, Vol.615 (7953), p.678-686

2023

Volltextzugriff (PDF)

Discovery of Acyl-Indole Derivatives as Pan-Serotype Dengue Virus NS4B Inhibitors

Journal of medicinal chemistry, 2023-07, Vol.66 (13), p.8808-8821

2023

Volltextzugriff (PDF)

Publisher Correction: A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction

Nature (London), 2021-11, Vol.599 (7883), p.E2-E2

2021

Volltextzugriff (PDF)

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles

Virology (New York, N.Y.), 2010-07, Vol.402 (2), p.338-346

2010

Volltextzugriff (PDF)

From Oxetane to Thietane: Extending the Antiviral Spectrum of 2′-Spirocyclic Uridines by Substituting Oxygen with Sulfur

ACS medicinal chemistry letters, 2022-12, Vol.13 (12), p.1879-1884

2022

Volltextzugriff (PDF)

Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library

Antiviral research, 2017-11, Vol.147, p.149-158

2017

Volltextzugriff (PDF)

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor

Antiviral research, 2011-08, Vol.91 (2), p.167-176

2011

Volltextzugriff (PDF)

Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes

Antiviral research, 2009-11, Vol.84 (2), p.142-149

2009

Volltextzugriff (PDF)

Biochemical screening assays to identify HIV-1 integrase inhibitors

Methods in molecular biology (Clifton, N.J.), 2013, Vol.1030, p.25

2013

Volltextzugriff (PDF)

Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1κ monoclonal antibody, in HIV-1 infected cells

Journal of virological methods, 2007, Vol.139 (1), p.17-23

2007

Volltextzugriff (PDF)

Binding kinetics, uptake and intracellular accumulation of F105, an anti-gpl20 human IgG1κ monoclonal antibody, in HIV-1 infected cells

Journal of virological methods, 2007, Vol.139 (1), p.17-23

2007

Volltextzugriff (PDF)

Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells

Journal of virological methods, 2007-01, Vol.139 (1), p.17-23

2007

Volltextzugriff (PDF)

Estimation of the optimal dosing regimen of escitalopram in dogs: A dose occupancy study with [11C]DASB

PloS one, 2017-06, Vol.12 (6), p.e0179927

2017

Volltextzugriff (PDF)

Urticaire : nouveautés et chronicité

Revue médicale suisse, 2023, Vol.19 (843), p.1730-1733

2023

Volltextzugriff (PDF)

In Vivo Evaluation of Blood Based and Reference Tissue Based PET Quantifications of [11C]DASB in the Canine Brain

PloS one, 2016-02, Vol.11 (2), p.e0148943-e0148943

2016

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(26)
Buchkapitel
(1)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B/NS3 and blocks replication organelle formation

Multiplexed multicolor antiviral assay amenable for high-throughput research

Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction

Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery

Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics

Therapeutics for flaviviral infections

A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships

Discovery of JNJ-1802, a First-in-Class Pan-Serotype Dengue Virus NS4B Inhibitor

Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates

Discovery of Acyl-Indole Derivatives as Pan-Serotype Dengue Virus NS4B Inhibitors

Publisher Correction: A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles

From Oxetane to Thietane: Extending the Antiviral Spectrum of 2′-Spirocyclic Uridines by Substituting Oxygen with Sulfur

Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor

Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes

Biochemical screening assays to identify HIV-1 integrase inhibitors

Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1κ monoclonal antibody, in HIV-1 infected cells

Binding kinetics, uptake and intracellular accumulation of F105, an anti-gpl20 human IgG1κ monoclonal antibody, in HIV-1 infected cells

Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells

Estimation of the optimal dosing regimen of escitalopram in dogs: A dose occupancy study with [11C]DASB

Urticaire : nouveautés et chronicité

In Vivo Evaluation of Blood Based and Reference Tissue Based PET Quantifications of [11C]DASB in the Canine Brain

Suchergebnisse filtern